Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,827 across all filing types
Latest filing 2019-09-11 M&A Activity
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
董事会关于哈药集团有限公司要约收购事宜致全体股东报告书
M&A Activity Classification · 95% confidence The document is titled as a "董事会关于哈药集团有限公司要约收购事宜致全体股东报告书" which translates to "Board of Directors Report to All Shareholders Regarding the Tender Offer of Harbin Pharmaceutical Group Co., Ltd." It contains detailed information about a tender offer (要约收购), including company background, shareholding structure, financial data, conflict of interest disclosures, and board recommendations. The document is a comprehensive report prepared by the board concerning a takeover bid or acquisition offer. It is not a simple announcement or a brief summary but a detailed report addressing shareholders about the tender offer. This fits the category of M&A Activity (Code: TAR), which covers announcements and documents related to merger proposals or takeover bids. The document length (15,000 characters) and content confirm it is a full report, not just an announcement or summary. Therefore, the correct classification is TAR with high confidence.
2019-09-11 Chinese
关于哈药集团有限公司要约收购公司股份之第二次提示性公告
M&A Activity Classification · 95% confidence The document is a detailed announcement regarding a tender offer (要约收购) by 哈药集团有限公司 to acquire shares of 哈药集团股份有限公司. It includes specifics about the offer price, offer period, procedures for shareholders to accept or withdraw the offer, and the purpose of the offer. The document is not a financial report, earnings release, or management discussion, but rather a formal announcement related to a takeover bid. This fits the definition of M&A Activity (TAR) filings, which cover announcements and documents related to merger proposals or takeover bids. The document length is 3596 characters, which is sufficient for a detailed announcement rather than a brief notice. Therefore, the correct classification is TAR with high confidence.
2019-09-11 Chinese
独立董事关于要约收购事宜的独立意见
M&A Activity Classification · 95% confidence The document is an independent opinion from the independent directors regarding a tender offer (要约收购) for the company's shares. It discusses the terms of the offer, the price, the offer period, and the independent directors' recommendation to shareholders. This is related to a merger or acquisition activity, specifically a takeover bid. The document is not a full report but an opinion on the tender offer. Therefore, it fits best under the category for M&A Activity (TAR). The document length is short and focused on the tender offer, not a full merger filing (MA).
2019-09-11 Chinese
关于哈药集团有限公司要约收购公司股份之第一次提示性公告
M&A Activity Classification · 95% confidence The document is a detailed announcement regarding a tender offer (要约收购) by 哈药集团有限公司 to acquire shares of 哈药集团股份有限公司. It includes specifics such as offer price, offer period, procedures for shareholders to accept or withdraw the offer, and the purpose of the offer. The content focuses on the acquisition proposal and related procedural details rather than financial results or management commentary. This fits the definition of M&A Activity (TAR) filings, which cover announcements and documents related to merger proposals or takeover bids. The document is not a full merger filing (MA) but an initial tender offer announcement, so TAR is the most appropriate classification. The document length is 3513 characters, which is sufficient for a detailed announcement but not a full report. Confidence is high due to the clear focus on a takeover offer and related procedural information.
2019-09-06 Chinese
八届二十三次董事会决议公告
Regulatory Filings Classification · 95% confidence The document is a board resolution announcement from Harbin Pharmaceutical Group Co., Ltd. It mentions the approval of the 2019 half-year report and asset impairment provisions. The document is short (613 characters) and states that the full half-year report is disclosed on the Shanghai Stock Exchange website, indicating this document is an announcement of the board meeting decisions rather than the full interim report itself. Therefore, it is not the interim report (IR) but rather a Regulatory Filing (RNS) as it does not contain substantive financial data but announces board resolutions and references the report elsewhere.
2019-08-30 Chinese
2019年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2019 半年度报告摘要" which translates to "2019 Semi-Annual Report Summary." It contains detailed financial data for the first half of 2019, including total assets, net profit, earnings per share, and cash flow figures. It also includes a comprehensive discussion and analysis of the company's business operations, market environment, product marketing, R&D, production, and future plans. The document is over 6,500 characters, indicating it is substantive and not merely an announcement or summary. The presence of detailed financial data and management discussion aligns with the characteristics of an Interim / Quarterly Report (IR). Therefore, the document should be classified as an Interim / Quarterly Report (IR). H1 2019
2019-08-30 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.